- Third quarter 2026 revenue increased 6% year-over-year and 3% sequentially to $5.3 million
- GAAP gross margin was 59%, compared to 60% in the third quarter of 2025; non-GAAP business-to-business-to-consumer ("B2B2C") gross margin remained at approximately 80% for the 11th consecutive quarter
- Revenue expected to accelerate at the end of 2026 and into 2027, driven primarily by the conversion of committed annual recurring revenue ("ARR"), including new enterprise customers and multi-condition expansions, such as Dario Women™ and Dario Sleep
- Expanding payer relationships from digital health behavior programming to integrated clinical care and medication management: working with a national health plan customer to bring GLP-1 therapy delivery into its member marketplace
- Signed one of New Jersey's largest health plans, representing 1.5 million covered lives, the third state health plan signed through the Amwell channel partnership in the past 12 months
- Operating loss decreased by 15% year-over-year while operating expenses declined by 10% year-over-year
- Cash, cash equivalents and short-term deposits totaled $31.2 million as of September 30, 2026
- More than 180 signed accounts across employers and health plans, with contracted and late-stage ARR of $13.1 million, more than 80% of it relates to multi-condition opportunities
- Conference call today, November 12, 2026 at 8:30 am ET
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced financial results for the third quarter ended September 30, 2026.
"In the second quarter of 2026, we described how Dario's business model is designed to support growth. We believe that our third quarter of 2026 shows that model is working, with multi-condition expansion within existing accounts and new health plan agreements through our channel partners," said Erez Raphael, Chief Executive Officer of DarioHealth. "At the same time, the market is moving toward the integrated platform we have spent more than a decade building. For years, the industry treated consumer health and payer-funded chronic care as two different businesses. We believe they are becoming one, and Dario sits exactly where they meet. Payers are moving from buying programs around a single therapy to buying a multi-condition integrated platform, as well as the therapy delivered inside a managed program, and we see that as a meaningful expansion of what Dario can do for payers and their members."
Today's consumer increasingly chooses the entry point into care, while the payer continues to fund the chronic condition behind it, and Dario believes the value in the market will move to whoever owns the path between the two. One of the largest national health insurers, an existing Dario customer, plans to implement a marketplace model that combines consumer choice with payer funding. This customer is working with Dario to extend the relationship from the digital program to delivery of the GLP-1 therapy itself. Dario views the convergence of these markets around access to specific therapies, inside a managed and measured program, as a significant opportunity.
Dario believes this shift will move chronic care management from single-condition apps to an AI-led, clinically governed system built on one member record. We believe Dario is one of very few platforms with consumer engagement and payer-grade evidence on the same member record, built over more than a decade on both sides: consumer roots and FDA-cleared connected devices in the home, more than 13 billion proprietary data points, more than 100 published studies and payer savings analyses prepared by third party, all on one platform. As payers bring specific therapies into the benefit, starting with GLP-1, Dario aims to connect access to therapy with the chronic conditions it already manages, supported by its existing member engagement capabilities and clinical and economic evidence.
Commercial Highlights:
Added New Enterprise Accounts Through Channel Partners and Expanded Within Existing Customers
- Signed one of New Jersey's largest health plans, representing approximately 1.5 million covered lives, through the Amwell channel partnership, with revenue contribution expected to begin in 2027.
- Approximately 40% of Dario's contracted and late-stage ARR comes from health plan ASO agreements, such as the new customer in New Jersey, which open access to a plan's self-insured employer book; revenue from these agreements builds over a multi-year horizon as each employer activates.
- Channel-sourced business grew more than 2x year-over-year, with growth across multiple contracting paths, including direct, reseller, health plan ASO or TPA, and marketplace.
- Expanded an existing contract with a leading regional grocery retailer, that has more than 200 stores and 19,000 employees, to add Dario Women™ program expected to become available to eligible insured employees in 2027.
Expanded Multi-Condition Platform
- Launched Dario Women™ and Dario Sleep, extending the Company's integrated platform into menopause, perimenopause and obstructive sleep apnea.
- Nearly 45% of Dario's current book of business consists of women over age 40, representing an opportunity to expand adoption of Dario Women™ across more of its existing enterprise customers.
- Dario views women's health, alongside men's health, as an additional growth driver, extending its multi-condition platform into conditions closely linked to cardiometabolic risk and selling into customer relationships it already holds.
Validation of Dario Platform's Clinical and Economic Value
- 3rd party analysis of 17 studies supports an estimated 2.5% to 7.2% annual reduction in total healthcare costs, representing approximately $3.8 million to $10.8 million in annual savings for a representative population of 20,000 covered lives.
- Analysis included findings of $5,077 in annual healthcare savings per user with type 2 diabetes and 23.5% fewer inpatient discharges compared with matched non-users.
DarioIQ: The Engine Underneath
- DarioIQ™ advanced from discrete engagement programs to an integrated AI system designed to predict member disengagement and trigger targeted interventions: members reached early returned within one week at 1.7 times the rate of comparable members not reached
- Results measured during the quarter now support the Company's expectation that DarioIQ could contribute to an increase of up to approximately 14% in engagement-based B2B2C ARR from existing customers
- DarioIQ, the Company's generative AI layer, is now deployed across the organization and is one of several contributors to the 10% year-over-year reduction in operating expenses
"We are adding large health plans through our channel partners and expanding inside the accounts we already serve," said Lara Dodo, Chief Operating Officer. "The rapid adoption of our new solutions like Dario Women reflects growing customer interest for more personalized, integrated care. We are meeting that demand with solutions that address interconnected chronic conditions and are demonstrated to deliver better health outcomes."
Third Quarter 2026 Financial Highlights:
- Revenue grew to $5.3 million, compared with $5.2 million in the second quarter of 2026 and $5.0 million in the third quarter of 2025. The year-over-year increase of 6% was primarily driven by continued growth in direct-to-consumer sales, which increased approximately 48% year-over-year. Business-to-business (B2B) and B2B2C revenue decreased compared to 2025, reflecting the non-renewal of several of Twill's legacy contracts, partially offset by growth from channel partners.
- Gross profit increased to $3.1 million, up approximately 4% year-over-year and down approximately 2% quarter-over-quarter.
- GAAP gross margin was 59%, compared with 60% in the third quarter of 2025 and 62% in the second quarter of 2026. The decline primarily reflects a lower IEEPA tariff refund benefit in the third quarter compared to the second quarter of 2026. Compared to the third quarter of 2025, the decline primarily reflects a higher direct-to-consumer mix, partly offset by lower hosting costs. Non-GAAP B2B2C gross margin remained at approximately 80% for the 11th consecutive quarter.
- Operating expenses were $11.2 million, down 10% year-over-year and up 16% quarter-over-quarter, while operating loss improved 15% year-over-year and increased 24% quarter-over-quarter. The sequential increase primarily reflects higher stock-based compensation, which was $2.2 million in the third quarter compared with $0.6 million in the second quarter.
- Cash, cash equivalents and short-term deposits totaled $31.2 million as of September 30, 2026.
"We grew revenue 6% year-over-year while reducing our operating expenses by 10% and our operating loss by 15%. Our B2B2C gross margin has remained strong, and we are focused on scaling that model," said Chen Franco-Yehuda, Chief Financial Officer. "With $31.2 million in cash, cash equivalents and short-term deposits, we believe we have the resources to execute on our priorities."
Third Quarter 2026 Financial Results
Revenue grew to $5.3 million for the third quarter of 2026, compared with $5.0 million in the third quarter of 2025 and $5.2 million in the second quarter of 2026, representing increases of 6% and 3%, respectively. The year-over-year increase primarily reflects growth in direct-to-consumer sales.
Gross profit was $3.1 million, compared with $3.0 million in the third quarter of 2025 and $3.2 million in the second quarter of 2026. Gross margin was 59.2%, compared with 60.2% in the third quarter of 2025 and 61.7% in the second quarter of 2026, primarily reflecting changes in revenue mix, including increased direct-to-consumer sales, partially offset by lower hosting costs. Gross margin in the second quarter included an IEEPA tariff refund benefit of approximately $0.4 million, compared with approximately $0.1 million in the third quarter.
Operating expenses declined year-over-year to $11.2 million, compared with $12.5 million in the third quarter of 2025 and $9.7 million in the second quarter of 2026, reflecting lower research and development and general and administrative expenses, partially offset by increased sales and marketing expenses compared to the year-ago period. Operating loss improved to $8.0 million, compared with $9.5 million in the third quarter of 2025 and $6.5 million in the second quarter of 2026.
Net loss decreased year-over-year to $8.8 million, compared with $10.5 million in the third quarter of 2025, and $7.9 million in the second quarter of 2026.
Non-GAAP operating loss (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the three months ended September 30, 2026 was $5.3 million compared to a non-GAAP operating loss of $6.0 million for the three months ended September 30, 2025, and non-GAAP operating loss of $5.3 million for the three months ended June 30, 2026.
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Nine Months Ended September 30, 2026
Revenue for the first nine months of 2026 was $16.1 million, compared with $17.1 million for the first nine months of 2025. The decrease primarily reflected non-recurring revenue from a pharmaceutical partner recognized in the prior-year period, partially offset by growth in B2B2C revenues from channel partners and direct-to-consumer sales.
Gross profit was $9.5 million for the first nine months of 2026, compared with $9.9 million in the prior-year period. Gross margin improved to 59.4%, compared with 57.6% for the first nine months of 2025, primarily reflecting lower amortization of technology and hosting costs and IEEPA tariff refund benefits of approximately $0.4 million.
Operating expenses decreased by 17% to $31.4 million for the first nine months of 2026, compared with $38.0 million for the first nine months of 2025, reflecting lower research and development, sales and marketing, and general and administrative expenses. Operating loss improved by 22% to $21.8 million, compared with $28.1 million in the first nine months of 2025.
Net loss improved by 23% to $25.0 million for the first nine months of 2026, compared with $32.7 million for the first nine months of 2025.
Non-GAAP operating loss (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the nine months ended September 30, 2026 was $16.0 million compared to Non-GAAP operating loss of $18.2 million for the nine months ended September 30, 2025.
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Conference Call Details
Date: Thursday, November 12th, 2026, 8:30 a.m. Eastern Time
Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)
Call me™: https://emportal.ink/4623c5K
Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to the scheduled start time.
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1775359&tp_key=4596015d94
Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately three hours after completion of the conference call through Thursday, November 26th, 2026. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1139413.
About DarioHealth Corp.
DarioHealth (Nasdaq: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.
Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expectations regarding revenue growth and acceleration, the timing and conversion of contracted and late-stage annual recurring revenue into recognized revenue, the onboarding, implementation and activation of new enterprise and health plan customers, the expansion of existing customer relationships, the anticipated benefits and commercial opportunities associated with Dario Women™, Dario Sleep and DarioIQ™, the potential impact of artificial intelligence on operating efficiency and member engagement, including the ability of DarioIQ™ to identify and predict member disengagement, deliver targeted interventions, improve member re-engagement and contribute to an increase of up to approximately 14% in engagement-based B2B2C annual recurring revenue from existing customers, as well as the expected operational efficiencies and cost savings associated with the deployment and expanded use of DarioIQ™ across the Company's operations, the expected benefits of its channel partnerships, the development and commercialization of integrated clinical care and GLP-1 medication access and management offerings, the anticipated convergence of consumer-directed and payer-funded healthcare, the potential clinical and economic benefits of its solutions, including estimated healthcare cost savings, and its liquidity, financial resources and ability to execute its business strategy. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contacts
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310
Zoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.com
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (UNAUDITED) | ||||||
U.S. dollars in thousands | ||||||
September 30, | December 31, | |||||
2026 | 2025 | |||||
ASSETS | ||||||
CURRENT ASSETS: | ||||||
Cash and cash equivalents | $ | 27,844 | $ | 21,803 | ||
Short-term bank deposits | 3,309 | 4,214 | ||||
Short-term restricted bank deposits | 288 | 229 | ||||
Trade receivables, net | 1,449 | 2,144 | ||||
Inventories | 3,538 | 4,316 | ||||
Other accounts receivable and prepaid expenses | 2,058 | 2,361 | ||||
Total current assets | 38,486 | 35,067 | ||||
NON-CURRENT ASSETS: | ||||||
Deposits | 110 | 80 | ||||
Operating lease right of use assets | 935 | 717 | ||||
Long-term assets | 469 | 304 | ||||
Property and equipment, net | 479 | 549 | ||||
Intangible assets, net | 14,526 | 15,931 | ||||
Goodwill | 57,427 | 57,427 | ||||
Total non-current assets | 73,946 | 75,008 | ||||
Total assets | $ | 112,432 | $ | 110,075 | ||
The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. | ||||||
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (UNAUDITED) | ||||||
U.S. dollars in thousands | ||||||
September 30, | December 31, | |||||
2026 | 2025 | |||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
CURRENT LIABILITIES: | ||||||
Trade payables | $ | 2,703 | $ | 2,928 | ||
Deferred revenues | 755 | 714 | ||||
Operating lease liabilities | 561 | 430 | ||||
Other accounts payable and accrued expenses | 5,154 | 5,251 | ||||
Total current liabilities | 9,173 | 9,323 | ||||
NON-CURRENT LIABILITIES | ||||||
Operating lease liabilities | 652 | 571 | ||||
Long-term loan | 31,247 | 30,747 | ||||
Warrant liability | 12 | 1,466 | ||||
Other long-term liabilities | 79 | 46 | ||||
Total non-current liabilities | 31,990 | 32,830 | ||||
STOCKHOLDERS' EQUITY ** | ||||||
Common stock of $0.0001 par value - authorized: 400,000,000 shares; issued and | 4 | 4 | ||||
Additional paid-in capital | 548,365 | 519,996 | ||||
Accumulated deficit | (477,100) | (452,078) | ||||
Total stockholders' equity | 71,269 | 67,922 | ||||
Total liabilities and stockholders' equity | $ | 112,432 | $ | 110,075 | ||
The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. | ||||||
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) | ||||||||||||
U.S. dollars in thousands (except stock and per share data) | ||||||||||||
Three months ended | Nine months ended | |||||||||||
September 30, | September 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
Revenues: | ||||||||||||
Services | $ | 2,554 | $ | 3,209 | $ | 7,964 | $ | 11,745 | ||||
Consumer hardware | 2,757 | 1,798 | 8,107 | 5,383 | ||||||||
Total revenues | 5,311 | 5,007 | 16,071 | 17,128 | ||||||||
Cost of revenues: | ||||||||||||
Services | 533 | 613 | 1,535 | 2,299 | ||||||||
Consumer hardware | 1,452 | 1,198 | 4,463 | 3,479 | ||||||||
Amortization of acquired intangible assets | 181 | 181 | 535 | 1,489 | ||||||||
Total cost of revenues | 2,166 | 1,992 | 6,533 | 7,267 | ||||||||
Gross profit | 3,145 | 3,015 | 9,538 | 9,861 | ||||||||
Operating expenses: | ||||||||||||
Research and development | $ | 2,295 | $ | 3,328 | $ | 6,780 | $ | 11,157 | ||||
Sales and marketing | 4,814 | 4,604 | 14,684 | 15,708 | ||||||||
General and administrative | 4,081 | 4,567 | 9,907 | 11,089 | ||||||||
Total operating expenses | 11,190 | 12,499 | 31,371 | 37,954 | ||||||||
Operating loss | 8,045 | 9,484 | 21,833 | 28,093 | ||||||||
Interest expenses | 1,094 | 1,157 | 3,367 | 1,923 | ||||||||
Other financial expenses (income), net | (272) | (175) | (545) | 2,645 | ||||||||
Total financial expenses, net | 822 | 982 | 2,822 | 4,568 | ||||||||
Loss before taxes | 8,867 | 10,466 | 24,655 | 32,661 | ||||||||
Income tax (benefits) | (18) | — | 367 | 22 | ||||||||
Net loss | $ | 8,849 | $ | 10,466 | $ | 25,022 | $ | 32,683 | ||||
Deemed dividend | $ | — | $ | 8,389 | $ | — | $ | 18,800 | ||||
Net loss attributable to common shareholders | $ | 8,849 | $ | 18,855 | $ | 25,022 | $ | 51,483 | ||||
Net loss per share: | ||||||||||||
Basic and diluted loss per share of common stock | $ | 0.73 | $ | 2.96 | $ | 2.46 | $ | 9.05 | ||||
Weighted average number of common stock used in | 12,060,332 | 3,138,106 | 10,179,366 | 2,673,794 | ||||||||
The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. | ||||||||||||
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (UNAUDITED) | ||||||
U.S. dollars in thousands | ||||||
Nine months ended | ||||||
September 30, | ||||||
2026 | 2025 | |||||
Cash flows from operating activities: | ||||||
Net loss | $ | (25,022) | $ | (32,683) | ||
Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation | 4,279 | 7,327 | ||||
Change in operating lease right of use assets | 331 | 319 | ||||
Amortization of acquired intangible assets | 1,405 | 2,357 | ||||
Depreciation and impairment | 158 | 247 | ||||
Change in fair value of warrant liability | (188) | (903) | ||||
Accrued interest on short term bank deposits | (45) | — | ||||
Non-cash financial expenses | 497 | 2,832 | ||||
Changes in operating assets and liabilities: | ||||||
Decrease in trade receivables, net | 695 | 2,429 | ||||
Decrease (increase) in other accounts receivable, prepaid expense and long-term assets | 108 | (470) | ||||
Decrease (increase) in inventories | 778 | (117) | ||||
Increase (decrease) in trade payables | (237) | 424 | ||||
Decrease in other accounts payable and accrued expenses | (64) | (1,495) | ||||
Decrease (increase) in deferred revenues | 41 | (723) | ||||
Decrease in operating lease liabilities | (337) | (248) | ||||
Other | (45) | 650 | ||||
Net cash used in operating activities | (17,646) | (20,054) | ||||
Cash flows from investing activities: | ||||||
Investment in short term bank deposit | (9,250) | — | ||||
Proceeds from maturity of short-term bank deposit | 10,200 | — | ||||
Purchase of property and equipment | (96) | (116) | ||||
Disposals of property and equipment | 6 | — | ||||
Net cash provided by (used in) investing activities | 860 | (116) | ||||
Cash flows from financing activities: | ||||||
Proceeds from AT-The-Market ("ATM") equity offerings | 104 | — | ||||
Issuance costs related to ATM equity offerings | (104) | — | ||||
Proceeds from issuance of common stock, preferred stock and warrant, net of issuance cost | 22,824 | 24,147 | ||||
Proceeds from borrowings on credit agreement | — | 31,700 | ||||
Repayment of long-term loan | — | (31,515) | ||||
Net cash provided by financing activities | 22,824 | 24,332 | ||||
Increase in cash, cash equivalents and restricted cash and cash equivalents | 6,038 | 4,162 | ||||
Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash equivalents | 3 | (19) | ||||
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 21,803 | 27,764 | ||||
Cash, cash equivalents and restricted cash and cash equivalents at end of period | $ | 27,844 | $ | 31,907 | ||
Supplemental disclosure of cash flow information: | ||||||
Cash paid during the period for interest on long-term loan | $ | 2,931 | $ | 2,260 | ||
Non-cash activities: | ||||||
Exercise of pre-funded warrants to common stock | $ | 1,266 | $ | 2,821 | ||
Right-of-use assets obtained in exchange for lease liabilities | $ | 549 | $ | — | ||
Purchase of property and equipment on credit | $ | 12 | $ | — | ||
The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. | ||||||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
U.S. dollars in thousands | ||||||||
Three months ended September 30, 2026 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 2,166 | (5) | (184) | 1,803 | |||
Gross Profit | 3,145 | 5 | 184 | 3,374 | ||||
Research and development | 2,295 | 124 | (24) | 2,210 | ||||
Sales and Marketing | 4,814 | (313) | (304) | 4,364 | ||||
General and Administrative | 4,081 | (1,764) | (11) | 2,132 | ||||
Total Operating Expenses | 11,190 | (2,201) | (339) | 8,706 | ||||
Operating Loss | $ | (8,045) | 2,206 | 523 | (5,332) | |||
Financing expenses | 822 | - | - | 822 | ||||
Income Tax (benefits) | (18) | - | - | (18) | ||||
Net Loss | $ | (8,849) | 2,206 | 523 | (6,120) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
U.S. dollars in thousands | ||||||||
Three months ended September 30, 2025 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 1,992 | (6) | (192) | 1,794 | |||
Gross Profit | 3,015 | 6 | 192 | 3,213 | ||||
Research and development | 3,328 | (389) | (30) | 2,909 | ||||
Sales and Marketing | 4,604 | (555) | (308) | 3,741 | ||||
General and Administrative | 4,567 | (2,000) | (17) | 2,550 | ||||
Total Operating Expenses | 12,499 | (2,944) | (355) | 9,200 | ||||
Operating Loss | $ | (9,484) | 2,950 | 547 | (5,987) | |||
Financing expenses | 928 | - | - | 982 | ||||
Net Loss | $ | (10,466) | 2,950 | 547 | (6,969) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
U.S. dollars in thousands | ||||||||
Nine months ended September 30, 2026 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 6,531 | (12) | (544) | 5,975 | |||
Gross Profit | 9,538 | 12 | 544 | 10,094 | ||||
Research and development | 6,780 | (82) | (80) | 6,618 | ||||
Sales and Marketing | 14,684 | (754) | (902) | 13,028 | ||||
General and Administrative | 9,907 | (3,431) | (36) | 6,440 | ||||
Total Operating Expenses | 31,371 | (4,267) | (1,018) | 26,086 | ||||
Operating Loss | $ | (21,833) | 4,279 | 1,562 | (15,992) | |||
Financing expenses | 2,822 | - | - | 2,822 | ||||
Income Tax | 367 | - | - | 367 | ||||
Net Loss | $ | (25,022) | 4,279 | 1,562 | (19,181) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
U.S. dollars in thousands | ||||||||
Nine months ended September 30, 2025 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 7,267 | (22) | (1,529) | 5,716 | |||
Gross Profit | 9,861 | 22 | 1,529 | 11,412 | ||||
Research and development | 11,157 | (1,356) | (104) | 9,697 | ||||
Sales and Marketing | 15,708 | (1,953) | (926) | 12,829 | ||||
General and Administrative | 11,089 | (3,996) | (46) | 7,047 | ||||
Total Operating Expenses | 37,954 | (7,305) | (1,076) | 29,573 | ||||
Operating Loss | $ | (28,093) | 7,327 | 2,605 | (18,161) | |||
Financing expenses | 4,568 | - | - | 4,568 | ||||
Income Tax | 22 | - | - | 22 | ||||
Net Loss | $ | (32,683) | 7,327 | 2,605 | (22,751) | |||
View original content to download multimedia:https://www.prnewswire.com/news-releases/dariohealth-reports-third-quarter-2026-financial-results-year-over-year-revenue-growth-and-operating-expense-reduction-302937690.html
SOURCE DarioHealth Corp.
